Zobrazeno 1 - 10
of 2 091
pro vyhledávání: ''
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Joanne Xiu, Michael J. Pishvaian, Ari M. Vanderwalde, Jia Zeng, Yasmine Baca, Sunnie S. Kim, John L. Marshall, W. Michael Korn, Anthony F. Shields, Axel Grothey, Heinz-Josef Lenz, Philip A. Philip, Mohamed E. Salem, Jimmy J. Hwang, Richard M. Goldberg, Michael Cerniglia
Publikováno v:
Mol Cancer Ther
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adeno
Autor:
Patrick Chaftari, Ray Y Hachem, Alexandre E. Malek, Natalie Dailey Garnes, Ying Jiang, Victor E. Mulanovich, Anne Marie Chaftari, Hiba dagher, Sai Ching J. Yeung, Issam I Raad
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8475-8482 (2021)
Cancer Medicine
Cancer Medicine
Background The Multinational Association for Supportive Care in Cancer (MASCC) risk index has been utilized to determine the risk for poor clinical outcomes in patients with febrile neutropenia (FN) in an emergency center (EC). However, this index co
Autor:
Gary Middleton, Alex G. Richter, Akshay J Patel, Ti-Myen Tan, Jonathan M. Blackburn, Babu Naidu
Publikováno v:
British Journal of Cancer
Background Lung cancer is the leading cause of cancer-related death worldwide. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. Despite careful case selection, a sig
Autor:
Eiji Shinozaki, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Izuma Nakayama, Daisaku Kamiimabeppu, Takeru Wakatsuki, Keitaro Shimozaki, Daisuke Takahari, Akira Ooki
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In contrast, carcinoembryonic antigen (CEA) is a conventional tumor marker for predicting recur
Publikováno v:
Clinical Lung Cancer. 22:e901-e910
Introduction While guidelines recommend testing for actionable biomarkers for patients with advanced or metastatic NSCLC, testing rates have varied. This study aimed to assess molecular testing patterns in a large network of US community-based oncolo
Autor:
Erica L. Carpenter, Stephanie S. Yee, Taylor A. Black, Allysia J. Mak, Austin L. Chien, Jamie Rosenstein, Carin R. Espenschied, Katie Quinn, Rebecca J. Nagy, Benjamin A. Silva, Sharyn I. Katz, Charu Aggarwal, Roger B. Cohen, Corey J. Langer, Aditi P. Singh, Martina I. Lefterova, Jeffrey C. Thompson, Christine Ciunci, Joshua Bauml, Lesli A. Kiedrowski
Publikováno v:
JCO Precis Oncol
PURPOSEAlthough the majority of patients with metastatic non–small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setting, predicting which patients will experience a dur
Autor:
Qiong Lyu, Jian Zhang, Peng Luo, Ting Wei, Weimin Ding, Linlang Guo, Weiliang Zhu, Qiongyao Wang, Manming Cao
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Cancer Medicine
Cancer Medicine
Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify patients
Autor:
Lanfang Li, Xianhuo Wang, Jin He, Sicong Zhang, Bin Meng, Jing Zhao, Xiaoxing Su, Shiyong Zhou, Lihua Qiu, Hengqi Liu, Tingting Zhang, Huilai Zhang, Xiubao Ren, Zhengzi Qian, Haifei Zhou, Xianming Liu, Wenchen Gong
Publikováno v:
British Journal of Haematology. 196:617-628
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established
Autor:
Yan-Fen Feng, Ling Deng, Hai-Yun Wang, Ying-Qing Li, Tao Tang, Fang Wang, Ya-Kang Long, Xin-Hua Yang, Xiao Zhang, Yuan He, Xu Zhang
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customiz